In this Review, Ackerman and colleagues describe the rationale for gene therapy to treat cardiac arrhythmias; discuss advantages and disadvantages of gene silencing, replacement and editing technologies; summarize vector modalities and delivery approaches; present examples of gene therapy strategies used for atrial and ventricular arrhythmias; and highlight the current challenges and limitations in the gene therapy field.
- Sahej Bains
- John R. Giudicessi
- Michael J. Ackerman